Theravance Biopharma, Inc.
TBPH · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -23.7% | 70.2% | -17.9% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 59.4% | 60% | 25.6% | 100% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -32.3% | -10.4% | -93.8% | -49.1% |
| Other Income/Exp. Net | $0 | $0 | $0 | $0 |
| Pre-Tax Income | -$0 | $0 | -$0 | -$0 |
| Tax Expense | -$0 | $0 | -$0 | $0 |
| Net Income | $0 | $0 | -$0 | -$0 |
| % Margin | 18.1% | 209.3% | -88.2% | -82.8% |
| EPS | 0.07 | 1.09 | -0.27 | -0.31 |
| % Growth | -93.6% | 503.7% | 12.9% | – |
| EPS Diluted | 0.07 | 1.08 | -0.27 | -0.31 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -9.5% | -8.8% | -91.1% | -40.5% |